Xylem: A Director Buys as Options Traders Pile Into Puts

Xylem has lost 17% in the past week. The stock closed Thursday at $90.76. Almost every analyst who covers it cut their target in the past 48 hours. And yet a board director spent nearly $1 million buying shares in the open market on Wednesday.

That divergence is the sharpest fact in the data right now.

The Director Purchase

D. Christian Koch bought 11,000 shares at $89.60 on October 29. The trade was discretionary, with no 10b5-1 plan attached. It was filed with the SEC the same day. At that price he committed $985,600 of his own money, buying into a stock that had just posted its worst single-day move in recent memory.

The 90-day net insider position now stands at 11,000 shares, with $985,600 of net open-market buying. That is the only open-market purchase in the recent trade history. The rest of the insider activity over the same period was grants and tax-withholding transactions, which carry no directional signal.

What the Analysts Did

The analyst community moved in the opposite direction. Barclays downgraded XYL to Equal-Weight from Overweight on October 29, cutting its target 25% to $104 from $139. UBS kept its Neutral rating but dropped its target to $99 from $112. Both moves followed JP Morgan's October 28 downgrade to Underweight, with a $90 target, one of the most bearish calls on the register.

The consensus mean price target now stands at $127.69. The stock trades at $90.76. That gap looks wide, but it will likely narrow as more desks complete their model updates. UBS already sits at $99 and JP Morgan at $90. The floor is being reset in real time.

The bear case centres on a weak 3Q26 print. Revenue missed across three of four segments. Full-year 2026 EPS guidance was cut to $5.40 to $5.45 from $5.55 to $5.70. Organic growth is now guided to flat for the year, with 4Q26 guided to minus 2% to minus 1%. China headwinds and deferred project spending are the cited pressure points.

The bull case, per Benzinga framing in the data, points to organic orders up 10% in 3Q26 and backlog rising to $5.5 billion. A planned restructuring into three cleaner segments takes effect January 1, 2027.

Options Positioning After Earnings

The put/call ratio moved sharply after the October 27 print. It hit 1.08 on October 29, 2.2 standard deviations above its 20-day mean of 0.86. One day earlier it sat at 0.74. The PCR 52-week high is 1.15, so current positioning is near the most defensive reading of the past year.

That shift means options traders added downside protection quickly after the earnings results. The PCR had been drifting lower in the sessions before the print, touching 0.72 on October 19. The post-earnings reversal to 1.08 is the fastest single-session move in the recent history shown.

Data Summary

• Stock: closed $90.76, down 16.9% over the past week
• Insider: D. Christian Koch bought 11,000 shares at $89.60 on October 29, no trading plan, $985,600 total
• Analyst downgrades: JP Morgan to Underweight ($90 target), Barclays to Equal-Weight ($104 target), within 48 hours of each other
• Consensus mean target: $127.69 across 11 analysts
• Put/call ratio: 1.08, 2.2 standard deviations above the 20-day mean
• Short interest: 4.0% of free float, down 12.3% over the past week
• Borrow availability: 729%, cost to borrow 0.44%
• EPS momentum 30-day factor rank: 10th percentile